Herpes zoster vaccine（recombinant，adjuvanted）
- Generic Name
- Herpes zoster vaccine（recombinant，adjuvanted）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于50岁及以上成人带状疱疹的预防。
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6138
- Registration Number
- NCT04869982
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath